View : 467 Download: 0
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
- Title
- A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
- Authors
- Park, Min Ho; Lee, Soo Jung; Noh, Woo Chul; Jeon, Chang Wan; Lee, Seok Won; Son, Gil Soo; Moon, Byung-In; Lee, Jin Sun; Kang, Sung Soo; Suh, Young Jin; Gwak, Geumhee; Kim, Tae Hyun; Yoo, Young Bum; Kim, Hyun-Ah; Kim, Min Young; Kim, Ju Yeon; Jeong, Joon
- Ewha Authors
- 문병인
- SCOPUS Author ID
- 문병인
- Issue Date
- 2020
- Journal Title
- BREAST
- ISSN
- 0960-9776
1532-3080
- Citation
- BREAST vol. 54, pp. 121 - 126
- Keywords
- Eribulin mesylate; Breast cancer; Retrospective study; Korean patients
- Publisher
- CHURCHILL LIVINGSTONE
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m(2) (equivalent to 1.4 mg/m(2) eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified. (C) 2020 The Author(s). Published by Elsevier Ltd.
- DOI
- 10.1016/j.breast.2020.09.004
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML